Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927579 | 1.00 | NNMT (0.49) | NNMTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL18228137 | 0.90 | NNMT (0.58) | NNMTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL4927538 | 0.78 | NNMT (0.60) | NNMTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL4914995 | 0.76 | NPSR1 (0.39) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4915001 | 0.76 | NPSR1 (0.39) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11523488 | 0.75 | ESR1 (0.50) | NPC1LMNARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18989339 | 0.75 | NNMT (0.56) | NNMTNPC1RAB9ASMN1; SMN2MKNK1 | |
| SCHEMBL29483301 | 0.75 | NNMT (0.56) | NNMTNPC1RAB9ASMN1; SMN2MKNK1 | |
| SCHEMBL8309518 | 0.75 | NNMT (0.56) | NNMTNPC1RAB9ASMN1; SMN2MKNK1 | |
| SCHEMBL5782172 | 0.75 | CXCR1 (0.53) | NNMTNPC1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | NNMT 2303/4885NPC1 381/4885LMNA 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.